Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
SynAct Pharma AB ( (SE:SYNACT) ) just unveiled an update.
SynAct Pharma’s board and management have voluntarily signed lock-up agreements preventing them from selling or otherwise disposing of their shares and related securities between 1 January and 30 June 2026, allowing only customary exceptions. The move comes as the company approaches key clinical milestones, including near-completion of patient recruitment and upcoming topline data from its Phase 2b ADVANCE trial in rheumatoid arthritis and a Phase 2a study in dengue virus, and is intended to underscore leadership’s confidence in SynAct’s strategy, support transparency around market-sensitive results, and signal commitment to long-term value creation for shareholders and potential partners.
More about SynAct Pharma AB
SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm that develops therapies targeting the resolution of inflammation via selective activation of the melanocortin system. Its portfolio comprises oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation-resolving activity, with a focus on helping patients restore immune balance in inflammatory diseases such as rheumatoid arthritis and certain viral infections.
Average Trading Volume: 145,199
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.09B
Learn more about SYNACT stock on TipRanks’ Stock Analysis page.